Endocrine Abstracts

Introduction: Type 2 diabetes, obesity and fatty liver disase are the most common comorbidities at the orgin of metabolic syndrome. Treatment of these conditions overlaps significantly. The most recent innovation in the armamentarium of pharmacotherapy of type 2 diabetes is Glp 1 agonist, More recent research on the effect of GLP-1 receptor agonist on weight loss, metabolic parameters and fatty liver disease are promising. The weight reduction offered by GLP-1 agonist treatmen...